Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 24;9:667. doi: 10.3389/fonc.2019.00667

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Kwon, Lee, Jeong, Woo, Han, Kang, Kim, Moon, Lee, Lee, Choi, Kwon, Song, Gong and Shin.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Comparison of clinical risk with the risk classification by the BCT score or Oncotype DX RS by age within each nodal subgroup. Proportion of patients within each risk group according to clinical risk assessment, BCT score, or RS according to age and nodal status. (A) Patients aged ≤50 years with lymph node-negative (LN-) breast cancer (n = 410). (B) Patients aged >50 years with lymph node-negative (LN-) breast cancer (n = 209). (C) Patients aged ≤50 years with lymph node-positive (LN+) breast cancer (n = 104). (D) Patients aged >50 years with lymph node-positive (LN+) breast cancer (n = 48). Clinical risk was determined using the modified Adjuvant! Online as reported in the MINDACT trial. Patients were divided into non-chemobenefit and chemobenefit groups by different RS ranges according to age group.